Moderna stock rallied, while Klarna and CoreWeave were among the week’s worst losers.

Non-accrual debt—one of a lender’s clearest signals of borrower distress—is rising, and private credit is entering a more ...

Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities after the company completed the sale of its marina segment for $5.5 billion in ...

Heat, drought, and wildfires are weighing on European growth and corporate profits, threatening to extend the economic ...

Federal Realty is a retail-based real estate investment trust that focuses on owning and operating high-quality shopping centers and mixed-use assets in eight of the largest metropolitan areas. It has ...

Additionally, the baby boomer generation is entering its senior years, and the 80-and-older population, which spends more than 4 times on healthcare per person than the national average, should almost ...

Imeik produces medical aesthetic fillers with two main segments, gel and solution, primarily in China. Historically dominated by foreign brands, domestic brands like Imeik have increased market share ...

As China’s largest duty-free and travel retail operator, China Tourism Group Duty Free has a substantial competitive edge because of its leading scale, solid relationship with suppliers, and ...

Bitcoin has, along with gold and silver, also benefitted from the U.S. Treasury's announcement Wednesday that it will raise its purchases of longer-term securities to at least $4 billion per operation ...

Trump, as a businessman who made infamous use of excess debts during his decades reeling from one corporate bankruptcy to another, is likely confusing the interest rate on corporate debts - like the ...

The following are median forecasts for next week's U.S. data from a survey compiled by The Wall Street Journal. Write to Donna Huneke at dataweekahead@wsj.com ...

The FTC's filing doesn't technically support Amgen or CareFirst of Maryland, the lawsuit's plaintiff. But it does state that Amgen's arguments on appeal cut against the longstanding framework that ...